tbuckley/cabot-search huggingface dataset:
Muscle-strengthening activities are associated with lower risk and mortality in major non-communicable diseases: a systematic review and meta-analysis of cohort studies
Authors: Haruki Momma, Ryoko Kawakami, Takanori Honda, Susumu S Sawada
Journal: British Journal of Sports Medicine (2022)

Objective To quantify the associations between muscle-strengthening activities and the risk of non-communicable diseases and mortality in adults independent of aerobic activities. Design Systematic review and meta-analysis of prospective cohort studies. Data sources MEDLINE and Embase were searched from inception to June 2021 and the reference lists of all related articles were reviewed. Eligibility criteria for selecting studies Prospective cohort studies that examined the association between muscle-strengthening activities and health outcomes in adults aged ≥18 years without severe health conditions. Results Sixteen studies met the eligibility criteria. Muscle-strengthening activities were associated with a 10–17% lower risk of all-cause mortality, cardiovascular disease (CVD), total cancer, diabetes and lung cancer. No association was found between muscle-strengthening activities and the risk of some site-specific cancers (colon, kidney, bladder and pancreatic cancers). J-shaped associations with the maximum risk reduction (approximately 10–20%) at approximately 30–60 min/week of muscle-strengthening activities were found for all-cause mortality, CVD and total cancer, whereas an L-shaped association showing a large risk reduction at up to 60 min/week of muscle-strengthening activities was observed for diabetes. Combined muscle-strengthening and aerobic activities (versus none) were associated with a lower risk of all-cause, CVD and total cancer mortality. Conclusion Muscle-strengthening activities were inversely associated with the risk of all-cause mortality and major non-communicable diseases including CVD, total cancer, diabetes and lung cancer; however, the influence of a higher volume of muscle-strengthening activities on all-cause mortality, CVD and total cancer is unclear when considering the observed J-shaped associations. Systematic review registration PROSPERO CRD42020219808.
DIET AND CORONARY ATHEROMA
Journal: JAMA (1962)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Canadian Medical Association Journal, Toronto
Journal: JAMA (1966)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Erratum
Authors: M Jmr, Iettebso Notes, Percy Lewis, W Kiarris, Rev Hobert Meciiney, B Fermusso, Thomas Randa'stown, L Oc, Charles Ildest, Shepherd Greystone, Elizabeth Neelney, Cb Y9 U' Gost
Journal: BMJ (1902)

Lecture on the Symptoms
Self-support of medical sciences through patents
Authors: G. Dalldorf
Journal: JAMA (1976)

THE ASSETS of many foundations are shrinking at a time when federal dispensations have tightened. As a result, wholly independent resources for support of medical research are now more attractive, if not more essential, than ever. An opportunity for self-support that is often neglected is income from commercially useful discoveries. An example is the substantial royalty income realized from nystatin, a patented antibiotic. Nystatin had been discovered in the laboratories of the Division of Laboratories and Research of the New York State Department of Health by two members of the scientific staff, Elizabeth Hazen, PhD, a mycologist, and Rachel Brown, PhD, a biochemist. They had christened it nystatin to commemorate its parent, the New York state laboratory. It is better known by one of its trade names, Mycostatin, suggested by the manufacturer to signify its cardinal activity, the inactivation of various fungi. The discovery raised various technical problems and one
Comparison of Social Needs Among US Insured Adults Before and During the Early Phase of the COVID-19 Pandemic
Authors: Douglas W. Roblin, Syed I. Khalid, Christopher Rouillard
Journal: JAMA Network Open (2022)

This cross-sectional study uses survey data linked with electronic health record data to compare the prevalence of social needs among US insured adults before vs during the early phase of the COVID-19 pandemic.
FRACASTORIUS, THE POET OF SYPHILIS
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Conceptual and Statistical Interpretation of a Systematic Review and Meta-Analysis on Patient Adherence to Lung-RADS–Recommended Screening Intervals in the United States
Authors: Mogana Sundari Rajagopal, Raghul Senthilnathan, Gothandam Km, Ravishankar Ram M, Suja Samiappan, Rama Jayaraj
Journal: Journal of Thoracic Oncology (2022)
HIV-1 shedding and chlamydial urethritis
Authors: J. J. Eron
Journal: JAMA (1996)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Understanding the Economic and Other Burdens of Terminal Illness for Patients and Their Caregivers
Journal: Annals of Internal Medicine (2000)

Summaries for Patients21 March 2000Understanding the Economic and Other Burdens of Terminal Illness for Patients and Their CaregiversSearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-132-6-200003210-00030 SectionsAboutFull Text ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail What is the problem and what is known about it so far?Terminal illness creates many hardships for both patients and the people who care for them. However, the specific nature and causes of these burdens have not been well described.Why did the researchers do this particular study?The researchers wanted to try to understand more clearly what factors lie behind the financial and nonfinancial burdens of terminal illness.Who was studied?Nine hundred eighty-eight patients who were judged by their physicians to be unlikely to live for more than 6 months, and 893 of these patients' caregivers. Relatives ... Author, Article, and Disclosure InformationAffiliations: The summary below is from the full report titled “Understanding Economic and Other Burdens of Terminal Illness: The Experience of Patients and Their Caregivers.”. It is in the 21 March 2000 issue of Annals of Internal Medicine (volume 132, pages 451-459). The authors are E.J. Emanuel, D.L. Fairclough, J. Slutsman, and L.L. Emanuel.Summaries for Patients are a service provided by Annals to help patients better understand the complicated and often mystifying language of modern medicine.Summaries for Patients are presented for informational purposes only. These summaries are not a substitute for advice from your own medical provider. If you have questions about this material, or need medical advice about your own health or situation, please contact your physician. The summaries may be reproduced for not-for-profit educational purposes only. Any other uses must be approved by the American College of Physicians-American Society of Internal Medicine. Previousarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoUnderstanding Economic and Other Burdens of Terminal Illness: The Experience of Patients and Their Caregivers Ezekiel J. Emanuel , Diane L. Fairclough , Julia Slutsman , and Linda L. Emanuel Metrics Cited byFactors Associated with Care Burden among Family Caregivers of Terminally Ill Cancer PatientsEducating Aging Service Agency Staff About Discussing End-of-Life Wishes 21 March 2000Volume 132, Issue 6Page: 451KeywordsCaregiversHealth carePatientsUrine ePublished: 15 August 2000 Issue Published: 21 March 2000 Copyright & PermissionsCopyright © 2000 by American College of Physicians. All Rights Reserved.Loading ...
Deaths Among Railroad Trespassers
Authors: Andrew Pelletier
Journal: JAMA (1997)

<h3>Objective.</h3> —To describe the characteristics of persons killed by trains while trespassing (ie, using railroad property for activities unrelated to railroad operations). <h3>Design.</h3> —Case series obtained from records of the state medical examiner. <h3>Setting.</h3> —North Carolina, 1990 through 1994. <h3>Subjects.</h3> —One hundred twenty-eight persons ranging in age from 7 to 84 years who were killed in 125 separate incidents. <h3>Results.</h3> —Of 224 railroad-related deaths during the study period, 128 cases (57%) involved trespassers. Trespasser fatalities typically involved unmarried male pedestrians 20 to 49 years of age with less than a high school education. Eighty-two percent of incidents occurred in the trespassers' county of residence, indicating that few deaths involved transients. Fatalities among railroad trespassers exhibited both geographic and temporal clustering. Seventy-eight percent of trespassers were killed while intoxicated (median alcohol level, 56 mmol/L [260 mg/dL]). <h3>Conclusions.</h3> —Deaths among trespassers are the leading cause of railroadrelated mortality in North Carolina. Greater efforts are needed to reduce this type of preventable injury. Prevention of trespasser fatalities is dependent on control of alcohol abuse, enforcement of existing laws, and education of the public regarding the dangers of railroad trespassing.
An Phase 2 Study of Lenalidomide in Combination with Oral Dexamethasone in Previously Untreated, Symptomatic Patients with Chronic Lymphocytic Leukemia (CLL)
Authors: Christine I Chen, Harminder Paul, Susi Snitzler, Lisa W Le, Ellen Nong Wei, Anthea Lau, James B Johnston, Spencer B. Gibson, Michelle L. Queau, Suzanne Trudel
Journal: Blood (2015)
<i>Forty-fifth Annual Report of the Trustees of the Boston City Hospital, with Report of the Superintendent, the Medical and Surgical Statistics, House Rules, with Rules for Admission, Discharge, and Government of Patients, etc.</i>For the forty-fifth year, February 1, 1908, to January 31, 1909, inclusive. (City of Boston, Printing Department, 1909.)
Authors: W. R. D.
Journal: American Journal of Psychiatry (1910)
Differential Diagnosis Between Postpacing Cardiac Memory and Ischemic T-Wave Inversion
Authors: Yun-Tao Zhao, Lei Wang
Journal: JAMA Internal Medicine (2022)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
The potential utility of fecal (or intestinal) microbiota transplantation in controlling infectious diseases
Authors: Rohma Ghani, Benjamin H. Mullish, Lauren A. Roberts, Frances J. Davies, Julian R. Marchesi
Journal: Gut Microbes (2022)

The intestinal microbiota is recognized to play a role in the defense against infection, but conversely also acts as a reservoir for potentially pathogenic organisms. Disruption to the microbiome can increase the risk of invasive infection from these organisms; therefore, strategies to restore the composition of the gut microbiota are a potential strategy of key interest to mitigate this risk. Fecal (or Intestinal) Microbiota Transplantation (FMT/IMT), is the administration of minimally manipulated screened healthy donor stool to an affected recipient, and remains the major 'whole microbiome' therapeutic approach at present. Driven by the marked success of using FMT in the treatment of recurrent Clostridioides difficile infection, the potential use of FMT in treating other infectious diseases is an area of active research. In this review, we discuss key examples of this treatment based on recent findings relating to the interplay between microbiota and infection, and potential further exploitations of FMT/IMT.
New York City Department of Health Response to Terrorist Attack, September 11, 2001
Journal: JAMA (2001)

In response to two jet aircraft crashing into and causing the collapse of the 110-storied World Trade Center (WTC) towers and the subsequent destruction of nearby portions of lower Manhattan, the New York City Department of Health (NYCDOH) immediately activated its emergency response protocol, including the mobilization of an Emergency Operations Center. Surveillance, clinical, environmental, sheltering, laboratory, management information systems, and operations were among the preestablished emergency committees. Because of its proximity to the WTC site, an emergency clinic was established at NYCDOH for triage and treatment of injured persons. NYCDOH focused its initial efforts on assessing the public health and medical impact of the attack and the resources needed to respond to it such as the care and management of large numbers of persons injured or killed by the crash; subsequent fire and building collapse; the health and safety of rescue workers; the environmental health risks (e.g., asbestos, smoke, dust, or chemical inhalation); other illnesses related to the disruption of the physical infrastructure (e.g., waterborne and foodborne diseases); and mental health concerns. Despite the evacuation and relocation of NYCDOH's headquarters, the department continued essential public health services, including death registration.
Tumor Immunity and Immunotherapy for HPV-Related Cancers
Authors: Achraf A. Shamseddine, Bharat Burman, Nancy Y. Lee, Dmitriy Zamarin, Nadeem Riaz
Journal: Cancer Discovery (2021)

Abstract Human papillomavirus (HPV) infection drives tumorigenesis in the majority of cervical, oropharyngeal, anal, and vulvar cancers. Genetic and epidemiologic evidence has highlighted the role of immunosuppression in the oncogenesis of HPV-related malignancies. Here we review how HPV modulates the immune microenvironment and subsequent therapeutic implications. We describe the landscape of immunotherapies for these cancers with a focus on findings from early-phase studies exploring antigen-specific treatments, and discuss future directions. Although responses across these studies have been modest to date, a deeper understanding of HPV-related tumor biology and immunology may prove instrumental for the development of more efficacious immunotherapeutic approaches. Significance: HPV modulates the microenvironment to create a protumorigenic state of immune suppression and evasion. Our understanding of these mechanisms has led to the development of immunomodulatory treatments that have shown early clinical promise in patients with HPV-related malignancies. This review summarizes our current understanding of the interactions of HPV and its microenvironment and provides insight into the progress and challenges of developing immunotherapies for HPV-related malignancies.
Alpelisib Extends PFS in <i>PIK3CA</i>-Mutant Breast Cancer
Journal: Cancer Discovery (2018)

In a phase III trial, patients with PIK3CA-mutant advanced breast cancer benefited from taking the PI3Kα inhibitor alpelisib in addition to fulvestrant endocrine therapy. The combination extended median progression-free survival, elevated response rates, and proved tolerable compared with fulvestrant plus placebo.
Pseudohypoparathyroidism
Authors: C V Dop, H R Bourne
Journal: Annual Review of Medicine (1983)

CD40 is a cell-surface member of the TNF (tumor necrosis factor) receptor superfamily. Upon activation, CD40 can license dendritic cells to promote antitumor T cell activation and re-educate macrophages to destroy tumor stroma. Numerous agonist CD40 ...Read More
Baseline Characteristics of Patients With HF With Mildly Reduced and Preserved Ejection Fraction
Authors: Scott D. Solomon, Muthiah Vaduganathan, Brian L. Claggett, Rudolf A. de Boer, David DeMets, Adrian F. Hernandez, Silvio E. Inzucchi, Mikhail N. Kosiborod, Carolyn S.P. Lam, Felipe Martinez, Sanjiv J. Shah, Jan Belohlavek, Chern-En Chiang, C. Jan Willem Borleffs, Josep Comin-Colet, Dan Dobreanu, Jaroslaw Drozdz, James C. Fang, Marco Antonio Alcocer Gamba, Waleed Al Habeeb, Yaling Han, Jose Walter Cabrera Honorio, Stefan P. Janssens, Tsvetana Katova, Masafumi Kitakaze, Bela Merkely, Eileen O’Meara, Jose Francisco Kerr Saraiva, Sergey N. Tereschenko, Jorge Thierer, Orly Vardeny, Subodh Verma, Pham Nguyen Vinh, Ulrica Wilderäng, Natalia Zaozerska, Daniel Lindholm, Magnus Petersson, John J.V. McMurray
Journal: JACC Heart Failure (2022)

This report describes the baseline clinical profiles and management of DELIVER (Dapagliflozin Evaluation to Improve the Lives of Patients With Preserved Ejection Fraction Heart Failure) trial participants and how these compare with those in other contemporary heart failure with preserved ejection fraction trials.The DELIVER trial was designed to evaluate the effects of the sodium-glucose cotransporter-2 inhibitor dapagliflozin on cardiovascular death, heart failure (HF) hospitalization, or urgent HF visits in patients with HF with mildly reduced and preserved left ventricular ejection fraction (LVEF).Adults with symptomatic HF and LVEF >40%, with or without type 2 diabetes mellitus, elevated N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels, and evidence of structural heart disease were randomized to dapagliflozin 10 mg once daily or matching placebo.A total of 6,263 patients were randomized (mean age: 72 ± 10 years; 44% women; 45% type 2 diabetes mellitus; 45% with body mass index ≥30 kg/m2; and 57% with history of atrial fibrillation or flutter). Most participants had New York Heart Association functional class II symptoms (75%). Baseline mean LVEF was 54.2 ± 8.8% and median NT-proBNP of 1,399 pg/mL (IQR: 962 to 2,210 pg/mL) for patients in atrial fibrillation/flutter compared with 716 pg/mL (IQR: 469 to 1,281 pg/mL) in those who were not. Patients in both hospitalized and ambulatory settings were enrolled, including 10% enrolled in-hospital or within 30 days of a hospitalization for HF. Eighteen percent of participants had HF with improved LVEF.DELIVER is the largest and broadest clinical trial of this population to date and enrolled high-risk, well-treated patients with HF with mildly reduced and preserved LVEF. (Dapagliflozin Evaluation to Improve the Lives of Patients With Preserved Ejection Fraction Heart Failure [NCT03619213]).